171557-31-6

Basic information

• Product Name: (BIS-TERT-BUTOXYCARBONYLMETHYL-AMINO)-ACETIC ACID
• Synonyms: (BIS-TERT-BUTOXYCARBONYLMETHYL-AMINO)-ACETIC ACID;N,N-Bis[2-(tert-butoxy)-2-oxoethyl]glycine;Glycine, N,N-bis[2-(1,1-diMethylethoxy)-2-oxoethyl]-;2-(Bis(2-(tert-butoxy)-2-oxoethyl)aMino)acetic acid
• CAS NO: 171557-31-6
• Molecular Formula: C13H23NO6
• Molecular Weight: 289.32482
• Mol File: 171557-31-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 399.2±37.0 °C(Predicted)
• Appearance: /
• Density: 1.129
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 1.96±0.10(Predicted)
• CAS DataBase Reference: (BIS-TERT-BUTOXYCARBONYLMETHYL-AMINO)-ACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (BIS-TERT-BUTOXYCARBONYLMETHYL-AMINO)-ACETIC ACID(171557-31-6)
• EPA Substance Registry System: (BIS-TERT-BUTOXYCARBONYLMETHYL-AMINO)-ACETIC ACID(171557-31-6)

Safety Data

• Hazardous Substances Data: 171557-31-6(Hazardous Substances Data)

Usage

General Description

(BIS-TERT-BUTOXYCARBONYLMETHYL-AMINO)-ACETIC ACID is a specific chemical compound that is used in various chemical and pharmaceutical applications. It is a derivative of acetic acid and contains a tert-butoxycarbonyl (Boc) protecting group. (BIS-TERT-BUTOXYCARBONYLMETHYL-AMINO)-ACETIC ACID is often utilized in the synthesis of peptide and protein molecules as a protecting group for the amino group. It is also used as a reagent in organic synthesis and as a building block for various chemical reactions. Additionally, it may have potential applications in the development of new pharmaceutical drugs and biotechnology products.

Upstream product

• 171557-57-6 (Benzyloxycarbonylmethyl-tert-butoxycarbonylmethyl-amino)-acetic acid tert-butyl ester 
• 49827-15-8 t-butyl iodoacetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 1351397-24-4 C₁₅H₂₇NO₆ 

Downstream Products

• 1351397-25-5 C₃₂H₅₂N₂O₁₁ 
• 1613025-37-8 C₃₄H₅₅N₅O₁₀ 

Relevant articles and documents

Three [...] -99m or rhenium -188 labeling ring RGD derivatives, its preparation method and comprising the said derivative as an active ingredient used for the diagnosis or treatment of diseases related to angiogenesis pharmaceutical composition

The present invention relates to a tricarbonyl technetium-99m or rhenium-188 label ring RGD derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases. The tricarbonyl technetium-99m or rhenium-188 label ring RGD derivative of the present invention has a high subnanomolar affinity to avss3 integrin (also called as a vitronectin receptor that is activated in an angiogenic action induced by a tumor, reflects a high tumor image after an animal in which cancer cells are transplanted received an initial intake of the tricarbonyl technetium-99m label ring RGD derivative, and acts exclusively upon cancer cells having selectively activated avss3 integrin because of a substantially low intake into the liver and intestines,; compared to existing known radioactive isotope label ring RGD derivatives. These results show that the rhenium-188 label derivative, a therapeutic nuclide using the same precursor as used in the technetium-99m label, effectively inhibits the growth of a tumor and demonstrates therapeutic efficacy when administered via tail vein injection to an animal model of a tumor, compared to a case where only saline has been injected, thereby making it useful as a medicine for the diagnosis or treatment of angiogenesis-related diseases.

Synthesis and biological evaluation of RGD peptides with the 99mTc/188Re chelated iminodiacetate core: Highly enhanced uptake and excretion kinetics of theranostics against tumor angiogenesis

To develop a companion set of RGD-based agents for diagnostic and radiotherapeutic purposes, facile incorporation of 99mTc(CO) 3 or 188Re(CO)3 into the same precursor produced, respectively, a structurally and functionally matched radiodiagnostic and radiotherapeutic - or theranostic - pair. This work presents the synthesis of two 99mTc-labeled RGD monomers (4 and 5) along with a 99mTc-labeled RGD dimer (6) and an investigation of the influence of the small-sized and negatively charged 99mTc-iminodiacetate (IDA) core on the in vitro and in vivo behavior of these three different RGD analogs for imaging integrin αvβ3 expression. Among the three 99mTc-IDA-RGD analogs, 6 exhibited the highest integrin binding affinity with an IC50 value of 0.5 nM and a tumor uptake with an ID/g value of 12.3 ± 5.15% at 60 min post-injection, whereas liver and intestinal levels remained relatively low with good metabolic stability (>97%), presumably because of the overall negative charge of the radiometal chelating system. Both 99mTc/188Re-labeled compounds (6 and 7), which were prepared from the precursor (18), provided a good tumor accumulation and a clearly visible image of the tumor with high contrast, as compared to the contralateral background in the U87-MG xenograft model. These data support the use of 99mTc- and 188Re-IDA-D-[c(RGDfK)] 2 as a matched radio-theragnostic pair that can be used to individualize radiotherapy for angiogenesis-dependent cancer.

A luminescent sensor for tyrosine phosphorylation

We have developed a luminogenic probe for tyrosine phosphorylation based on a short peptide sequence containing an iminodiacetate moiety near the site of phosphorylation. In response to kinase activity, the probe provides a strong luminescence enhancement, resulting from the increased ability of the probe to bind and sensitize Tb3+ and Eu3+ ions upon phosphorylation.